Leo Guthart Purchases 20,000 Shares of Immune Design Corp (IMDZ) Stock
Immune Design Corp (NASDAQ:IMDZ) major shareholder Leo Guthart acquired 20,000 shares of Immune Design stock in a transaction on Monday, January 8th. The stock was acquired at an average price of $3.90 per share, with a total value of $78,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Leo Guthart also recently made the following trade(s):
- On Friday, October 27th, Leo Guthart purchased 2,439,000 shares of Immune Design stock. The shares were purchased at an average price of $4.10 per share, with a total value of $9,999,900.00.
- On Tuesday, October 24th, Leo Guthart purchased 60,000 shares of Immune Design stock. The shares were purchased at an average price of $4.65 per share, with a total value of $279,000.00.
- On Thursday, October 19th, Leo Guthart purchased 10,000 shares of Immune Design stock. The shares were purchased at an average price of $6.09 per share, with a total value of $60,900.00.
Immune Design Corp (NASDAQ:IMDZ) traded down $0.10 during trading hours on Wednesday, hitting $3.83. The company’s stock had a trading volume of 263,500 shares, compared to its average volume of 454,850. Immune Design Corp has a 1 year low of $3.50 and a 1 year high of $13.05. The stock has a market cap of $183.83, a PE ratio of -1.80 and a beta of 2.36.
Several large investors have recently added to or reduced their stakes in IMDZ. State of Wisconsin Investment Board purchased a new position in shares of Immune Design during the 2nd quarter valued at about $117,000. Alliancebernstein L.P. bought a new position in Immune Design during the 2nd quarter worth approximately $118,000. Virtu KCG Holdings LLC bought a new position in Immune Design during the 2nd quarter worth approximately $153,000. Dimensional Fund Advisors LP grew its position in Immune Design by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Immune Design by 53.9% during the 2nd quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 6,896 shares during the last quarter. 29.34% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently weighed in on the company. Royal Bank of Canada assumed coverage on Immune Design in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target for the company. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. ValuEngine downgraded Immune Design from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cowen reiterated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Finally, Wells Fargo & Co cut Immune Design from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $13.06.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.